WilmerHale Counsels Merrimack in $25M Debt Facility

Download IconDownload Print IconPrint

WilmerHale Counsels Merrimack in $25M Debt Facility

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a clinical-stage oncology company focused on biomarker-defined cancers, announced on July 2, 2018, the closing of a $25 million term loan with Hercules Capital (NYSE:HTGC), $15 million of which was funded at closing. Merrimack's funds are projected to help the company's planned operations into the first quarter of 2020.

The WilmerHale team representing Merrimack is led by Jamie Class, and includes John Sigel and Brandt Tierney.

Read Merrimack’s press release regarding the financing.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel